Contraindications Discussed in Clinical Psychedelic Research

The legal picture comes first , every time

Psilocybin is a Schedule 9 prohibited substance under Australia's Poisons Standard. Possession, use, or supply outside a very narrow regulatory pathway is a criminal offence. Full stop. The narrow pathway that does exist was created in February 2023, when the TGA rescheduled psilocybin to Schedule 8 (controlled drug) for use by Authorised Prescribers only , and even then, solely within the specific indication framework the TGA has outlined. Outside that pathway, the substance remains Schedule 9. No self-administration, no informal "ceremony", no imported product exists legally in Australia without serious criminal exposure. That framing has to come before anything else I write here.

This article is about the contraindications that appear in peer-reviewed clinical research , not instructions, not a protocol, not a recommendation to seek access. Understanding the safety boundaries researchers have documented is educational. It is not a substitute for medical advice, and it is not an invitation to obtain or use anything.

Why contraindications appear in psychedelic research at all

Clinical trials of psilocybin and other classic psychedelics (LSD, DMT, mescaline analogues) are conducted under strict ethical and regulatory oversight. Researchers screen participants carefully; not simply to protect study integrity, but because certain physiological and psychological profiles appear to carry meaningfully higher risk of adverse outcomes during and after sessions. The exclusion criteria in those trials are the clearest published record we have of where researchers draw the line.

I've spent a fair bit of time lately going back through the published trial protocols, the kind of reading that goes well past midnight when I should be practising chord changes instead. What strikes me is how consistently certain categories of concern recur across otherwise quite different studies. That consistency is worth examining.

Cardiovascular considerations documented in trial protocols

Psilocybin acts primarily as a partial agonist at serotonin 5-HT2A receptors. One downstream effect, well-documented in pharmacological literature, is transient increases in heart rate and blood pressure. Several published trials, including the Imperial College London and Johns Hopkins University protocols; explicitly excluded participants with significant cardiovascular conditions, uncontrolled hypertension, or a family history of serious cardiac arrhythmia.

The mechanism here relates to serotonergic activity broadly. Serotonin receptors are expressed in cardiac tissue, and the 5-HT2B receptor in particular has been associated with valvular changes in the context of sustained agonism (as seen historically with some pharmaceutical serotonergic agents). Most clinical psychedelic protocols involve single or very few administrations, which researchers note is a different exposure profile, but cardiovascular monitoring remains standard in trial settings.

This is also relevant when considering drug interactions. The pharmacokinetics of psilocybin, its conversion to psilocin via alkaline phosphatase, its plasma half-life, and its hepatic metabolism; mean that concurrent medications affecting serotonin reuptake or cardiovascular tone are treated as significant risk factors in trial screening.

Personal or family history of psychosis

This is probably the most consistently cited exclusion criterion across the clinical literature, and honestly I think it deserves more careful public explanation than it typically gets. A personal or family history of schizophrenia, schizoaffective disorder, or other primary psychotic disorders has been an exclusion criterion in virtually every major psilocybin trial to date.

The reasoning is pharmacological and clinical. Psilocybin's primary receptor target, the 5-HT2A receptor, is implicated in the neurobiology of psychosis. Antipsychotic medications, many of which act as 5-HT2A antagonists, are observed to attenuate or block the subjective effects of psilocybin in research settings. The concern is that 5-HT2A agonism may precipitate or exacerbate psychotic episodes in individuals with that vulnerability, potentially in a lasting way.

The risk of Hallucinogen Persisting Perception Disorder (HPPD), a rare but documented phenomenon involving persistent perceptual disturbances following psychedelic use, is also noted in the literature, though its incidence rates and predisposing factors remain subjects of active research.

Bipolar disorder; a more nuanced picture in the research

Bipolar spectrum disorders occupy a more complicated space in clinical trial exclusion criteria. Most trials have excluded participants with bipolar I disorder, and many have excluded bipolar II. The concern is primarily around the potential for triggering manic or hypomanic episodes.

Some researchers have begun examining whether certain subtypes of bipolar disorder might eventually be studied differently, but at the moment, the published clinical literature overwhelmingly treats active or poorly stabilised bipolar disorder as a contraindication. I'd be cautious about anyone who presents this as a settled or straightforward area, it isn't.

Pharmacological interactions: lithium and serotonergic agents

Lithium is explicitly flagged across multiple research protocols as an interaction concern. Case reports in the literature describe seizures in individuals who combined lithium with psychedelics, and animal model data has suggested heightened neurotoxicity risk in that combination. Given that lithium is commonly prescribed for bipolar disorder, this creates a compounding exclusion factor in most trial designs.

Serotonergic medications more broadly, selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs); are treated with varying degrees of concern depending on the protocol. Some researchers have noted that chronic SSRI use appears to attenuate psilocybin's subjective effects, which raises both efficacy and safety interpretation questions. MAOIs are flagged more severely: the combination can theoretically produce serotonin syndrome, which is a medical emergency.

This pharmacological complexity underscores why the Special Access Scheme and Authorised Prescriber pathway in Australia exist. Clinical oversight isn't bureaucratic box-ticking, it's the mechanism by which medication history, co-prescriptions, and individual risk factors can actually be assessed by a qualified practitioner.

Active suicidality and psychological instability

Most published trials have excluded individuals in acute psychological crisis, including those with active suicidal ideation with intent or plan. This is worth noting carefully, because some public commentary has collapsed this into a broader claim about psychedelics and suicide risk, and the research picture is more specific than that framing suggests.

Exclusion of acutely suicidal individuals from trials isn't a signal that psychedelics are uniformly contraindicated for everyone who has experienced suicidal thoughts. It reflects the reality that acute crisis states require stabilisation before any experimental intervention, and that controlled research conditions can't adequately manage acute crisis risk. The distinction matters, and conflating the two does a disservice to both safety and scientific accuracy.

Pregnancy, breastfeeding, and developmental considerations

Clinical trials have uniformly excluded pregnant and breastfeeding participants. The reasons are straightforward: there is essentially no safety data in these populations, and psilocin crosses biological membranes. Some preclinical research has examined serotonergic signalling in foetal development, but extrapolating from that to clinical guidance requires far more evidence than currently exists. Researchers have applied a precautionary standard here, and that seems reasonable given the evidence gap.

What this means in the current Australian regulatory context

The Authorised Prescriber pathway; established under the TGA's February 2023 rescheduling decision, requires that any prescribing practitioner hold AP status approved by the TGA, and that they apply the clinical judgement this article describes. Contraindication screening isn't optional in that framework; it's embedded in the professional and regulatory obligations that come with prescribing a Schedule 8 controlled drug.

Outside that pathway, possession or use of psilocybin remains a Schedule 9 prohibited substance offence. The Australian Drug Foundation's published resources confirm that penalties for possession and supply of Schedule 9 substances vary by state and territory but carry the potential for serious criminal consequences. "I read about it online" is not a legal defence, and neither is "it was for personal use."

For anyone wanting to understand the broader regulatory scaffolding, the TGA's own published documentation on the 2023 rescheduling decision remains the primary source. I'd also point to the published Imperial College and Johns Hopkins trial protocols in peer-reviewed journals, they're the most transparent available records of how clinical researchers actually structure safety screening.

Sources

• Scheduling Delegate's Final Decisions: February 2023; Therapeutic Goods Administration (TGA)
• Magic Mushrooms Drug Facts, Australian Drug Foundation (ADF)
• Clinical Investigations of Psilocybin: Participant Safety and Adverse Events, National Library of Medicine (NCBI/NIH)
• Survey of Subjective "God Encounter" Experiences and Safety; Griffiths et al., NCBI/NIH

, Daniel Okoro, Psychedelic science & law writer